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therapeutic conclusions. Colonization with fungi has been
identiﬁed as an independent risk factor for invasive myco-
sis. In addition to colonization with a single species, the
combination of different fungal species may be of interest.
Methods: In a prospective study we analyzed samples
taken from 411 patients after admission to our ICU. Swabs
from nostril, throat and anus and specimens of tracheal
secretions and urine were taken and cultured on CHROM-
Agar.
Results: Positive results were found in 798 (42.7%) of
all 1868 samples. Of these, 618 were positive for a single
species, 158 for two species, and 22 for three species. Con-
cerning distribution of species, we found Candida albicans
in 69.3%, Candida glabrata in 34.8% and Candida tropi-
calis in 8.1% of all positive specimens. In 90 cases, cultures
grew Candida albicans together with Candida glabrata, in 23
cases, Candida albicans together with Candida tropicalis, in
12 cases, Candida albicans together with Candida glabrata
and Candida tropicalis. Most frequently, a mixed coloniza-
tion was detected from throat swabs (74 mixed, out of 281
positive cultures, 26.3%), followed by tracheal secretions
(35 mixed, out of 153 positive cultures, 22.9%) and anal
swabs (48 mixed, out of 235 positive cultures, 20.4%). In con-
trast, a mixed colonization was signiﬁcantly less frequent in
nasal swabs (18 mixed, out of 136 positive cultures, 13.2%)
and in urine (5 mixed, out of 56 positive cultures, 8.9%).
Conclusion: A large proportion of samples showed growth
of yeasts. Out of culturally positive, in 22.6% were found
more than one species. Colonization with more than one
species was found to be signiﬁcantly more frequent in
throat, trachea and anus compared to nose and urine.
doi:10.1016/j.ijid.2010.02.1744
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Background: In recent years a shift towards candida non
albicans has been reported from candidemia trials. A species
shift in candidemia is important, since newer guidelines
favor upfront echinocandins containing an economic bur-
den. This has to be balanced with medical needs. Trends
of epidemiology outside of controlledl trials are therefore
of particular interest.
We analyzed all candida isolates from ﬁve Munich teach-
ing hospitals (3500 beds). The objective was to compare all
candida isolates and all candidemia eps in 2008 and 09 with
the previous 2ys (data in brackets).
Methods: Between 01/08 and 10/09 a total of 15258 can-
dida isolates were detected. No routine azole prophylaxis
was given beside high risk cancer pts.There was no hint for
a seasonal cluster during the study periods.
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Results: While 64,20% (64.9%) were C. albicans, 7,5%
7.8%) were C. glabrata ahead of C. tropicalis with 4,7
4.6%), while in 1,74% C. krusei was detected. 384 isolates
ere obtained from two hemato-oncology units with C. albi-
ans 52, 3% (80.5%) ahead of C. glabrata 8,1% (7.8%), C.
ropicalis 5,4% (4.7%) and C. krusei (1.9%). A total of 148
solates were detected from blood cultures. C. albicans was
ound to be less common in candidemia 57,5% (58.9%), but
ominated far ahead of C. glabrata 17,1% (20.9%), C. trop-
calis 6,8% (7.0%), C. parapsilosis 4,8% (5.4%) and C. krusei
,7% (3.1%). 28.6% of candidemia eps was by C glabrata in
ancer pts in 2008 an 09.
Conclusion: Although a shift towards C. non albicans has
een described elsewhere, our study indicated C. albicans
emains the leading species. No further shift to C. glabrata
nd C. tropicalis has been observed within the last 4 years.
f candida is found, C. glabrata is detected about 2.3-fold
ore often and accounts for 17% of candidemia eps, with
n even 3.8-fold higher risk in cancer pts. Echinocandins,
ewer azoles and lipid AmB therefore seem to be justiﬁed
or upfront candidemia Rx, in particular cancer and those
ts with an unstable clinical condition.
oi:10.1016/j.ijid.2010.02.1745
0.005
nti-Saccharomyces cerevisiae (ASCA) antibody levels in
subgroup of patients with ulcerative colitis, Crohn’s dis-
ase, GI Behcet, and GI tuberculosis: Correlations with
isease duration, activity, and extension
. Aslan1,∗, B. Kocazeybek1, A. Celik2, Y. Erzin3, I.
atemi2, G. Hatemi2, H. Yazici 2
Istanbul University Cerrahpasa Faculty of Medicine,
urkey, Turkey
Istanbul University Cerrahpasa Faculty of Medicine, Istan-
ul, Turkey
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Background: Clinical utility of serological markers in
nﬂammatory bowel disease (IBD) diagnosis and differen-
iating is controversial. Recently ASCA has been found to
ave some correlation with the complication and recurrent
urgery rate Our aim was to seek for correlations between
SCA levels and disease duration, extension, activity, CRP
evels, and use of immmunosupressive therapy
Methods: A total of 41 consecutive patients (16 UC,
0CD, 3 GI BD, and 2 GI Tb; 34 women, 7 male) were ana-
yzed regarding ASCA IgG levels with anti-ASCA IgG ELISA kit
Euroimmune, Lübeck, Germany), the cut-off value being
5 U/ml. Disease activity was assessed using SEO for UC and
DAI for CD, GI BD, and GI Tb patients, respectively. Addi-
ionally, a simpliﬁed endoscopic extension score was used
y dividing the colon into six equal units and accepting ileal
nvolvement as an additional unit in an ordinal manner. SPSS
5 for Windows is used for data collection and are expressed
s means, with SD of the mean calculated when appropriate.
orrelations were sought using Pearson’s and Spearman’s
orrelation coefﬁcient and multivariate analysis was per-
ormed by using a stepwise regression model. p < 0.05 was
egarded as signiﬁcance.
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Results: The mean age (±SD) of patients was
7.31± 10.65 years, 83% of them being female, and
4 out of 41 (34%) patients were in an active phase of
he disease. ASCA IgG levels signiﬁcantly were correlated
ith sypmtom duration x disease extension score factorial
r = 0.481, p = 0.001), disease duration x disease extension
core factorial (r = 0.468, p = 0.002), and SES-CD (r = 0.480,
= 0.001). No correlations were noted between ASCA
nd CRP levels and clinical activity. On age-sex adjusted
tepwise regression analysis, sypmtom duration, disease
uration, disease extension, and SES-CD entered into
he model, disease extension score was found to be the
nly independent predictor of ASCA IgG levels (R2 = 0.1,
= 0.044).
Conclusion: Although the aetiopathogenesis of inﬂam-
atory bowel disease remains unsolved, a serologic
nti-microbial response exists one of them being ASCA. Dis-
ase and symptom duration, disease extension but clinical
ctivity have signiﬁcant correlations with ASCA levels point-
ng out to the importance of sustained immunological stimuli
s a triggering process. These results might provide new
nsights into the mechanisms of epithelial responses to anti-
ens and ideas for therapies.
oi:10.1016/j.ijid.2010.02.1746
0.006
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Background: The role of perinuclear antineutrophil
ytoplasmic antibodies (pANCA) and anti-Saccharomyces
erevisiae antibodies (ASCA) assessment in inﬂammatory
owel disease (IBD) diagnosis and differentiating is still
mprecise and controversial.
Methods: The aim of the study was to determine the
ccuracy of pANCA and ASCA in patients with speciﬁc intesti-
al inﬂammations, namely UC, CD, GI Behcet (GI-BD), GI
uberculosis (GI-TBC) which are under the same inﬂam-
atory bowel registry, compared to tree control groups;
amely, Celiac disease, irritable bowel syndrome (IBS)
atients and healthy controls (HC). A total of 493 subjects
102 with UC, 63 with CD, 13 with GI BD, 10 with GI Tb, 130
ith IBS, 10 with Celiac disease, and 165 HC) ﬁrstly admitted
o our weekly IBD outpatient practice of a tertiary referral
enter were analyzed regarding pANCA and ASCA Ig A-G via
mmunoﬂuorescent assay (IFA) with commercially available
FA kits (Euroimmune, Lübeck, Germany).
Results: The prevalence of any pANCA or ASCA positiv-
ty and age and sex of patients are summarized in Table 1.
n UC patients the prevalence of pANCA was 42.2%, which
as signiﬁcantly higher than in CD-4.8% (p = 0.000). ASCA
as found signiﬁcantly more often in CD-54% than in UC
(
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atients-4.8% (p = 0.000). The prevalence of ASCA in BD
atients-15.4% disclosed a signiﬁcant difference compared
o CD patients (p = 0.014), but the prevalence of ASCA in TBC
atients showed no signiﬁcant difference compared to CD or
D patients.
Table 1: Prevalence of pANCA and ASCA in different sub-
roups.Marked values(p < .05)
pANCA(+) ASCA(+) age male(%)
BS (n = 130) 1(0.8%) 4(3.07%) 40.84(SD 12.69)* 42.3(a)
C (n = 165) 1(0.6%) 7(4.2%) 35.07(SD 10.49)*;** 40(b)
C (n = 102) 43 (42.2%) 11(10.8%) 40.72(SD 13.44)** 50(c)
D (n = 63) 3 (4.8%) 34(54%) 37.56(SD 12.65) 38.1(d)
I-BD (n = 13) 0 2(15.4%) 32.11(SD 8.89) 61(e)
eliac Disease (n = 10) 0 4(40%) 36.77(SD 7.94) 0(a;b;c;d;e;f)
I-TBC (n = 10) 1(10%) 3(30%) (SD 9.96) 70(f)
Conclusion: Our results conﬁrm that in clinical practice
SCA is not speciﬁc enough to be a useful tool in differential
iagnosis of any speciﬁc inﬂammation. However, it may have
ome value in screening of normal population for any bowel
nﬂammation. pANCA may have a better clinical value in the
iscrimination of UC from other intestinal inﬂammations.
oi:10.1016/j.ijid.2010.02.1747
0.007
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Background: Pentamycin is a broad-spectrum polyene
acrolide and the available intravaginal formulation
FemiFect®, 3mg vaginal tablets, Lumavita AG, Basel,
witzerland) is effective in the treatment of vaginal tri-
homoniasis, candidiasis sustained by Candida albicans and
ixed infections (Clin. Ter. 92: 137-142, 1980; Internet Jour-
al of Gynecology and Obstetrics 11(1), 2009). Because
easts other than C. albicans are frequently isolated in
ecurrent or mixed forms of vaginal mycoses, it is impor-
ant to assess the activity of pentamycin against these
pecies, which also exhibit reduced susceptibility to conven-
ional antimycotic drugs. Therefore, the objective of this
tudy was to compare the in-vitro activity of pentamycin
ith that of nystatin, amphotericin B, and ﬂuconazole
gainst strains of nonalbicans candidal species and strains of
accharomyces cerevisiae isolated from medical samples.
Methods: Two collections of clinical isolates included in
otal 40 strains of C. glabrata, 41 strains of C. parapsilo-
is, 30 strains of C. tropicalis, 30 strains of C. krusei and
0 strains of S. cerevisiae. In-vitro susceptibility testing was
erformed using the broth microdilution method developed
y the Clinical and Laboratory Standards Institute (CLSI),
ocument M27-A2. The minimal inhibitory concentration
MIC) of each tested drug was read visually after 24 hours
nd 48 hours of incubation.
Results: The MIC at which 90% of strains of each yeast
pecies were inhibited (MIC90) after 48 hours of incubation
